Some reading material here.
Various recent articles / discussions from 2014 on using oral fluid testing over urine testing:
Australia:
http://www.asu.asn.au/blogs/entry/oral-fluid-drug-testing-over-urine-testing-three-tribunal-cases-and-three-wins
UK:
http://www.cansfordlabs.co.uk/toxicology-oral-fluid-drug-testing-2/
USA
http://www.cannamm.com/services/drug-alcohol-testing/oral-fluidsaliva-drug-testing/
Here's an article on Orasure, who are listed on the NASDAQ (OSUR) and who have a similar focus to SBN, being the "development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using proprietary oral fluid technologies" now looking at personalised medicine.
Article:
http://www.fool.com/investing/general/2014/03/05/why-orasure-technologies-inc-shares-jumped.aspx
SBN mentioned recently genomic testing and personalised medicine as an area of interest.
Orasure are obviously well ahead of SBN, already generating revenue and with a market cap of around $500m vs SBN $4m. Will do some more research on Orasure over the weekend.
Changed my sentiment to "buy"
Add to My Watchlist
What is My Watchlist?